 |
Educational programme for Clinicians and Scientists |
|
|
Oral iron chelators in the treatment of thalassemias
and other diseases |
|
|
Advances in the treatment of iron overload with L1-
Deferiprone, Deferoxamine and their combination. |
|
|
The use of effective dose protocols in iron
chelation therapy. |
|
|
New iron chelators under development: Deferasirox
(ICL670), Deferitrin (GT-56 252), L1NAll. |
|
|
Future strategies and developments in iron
chelation. |
|
|
Iron chelation in Sickle cell anaemia,
Myelodysplasia, Haemolytic anaemia, Renal dialysis,
Cancer and other diseases. |
|
|
Iron metabolism and iron containing proteins
in normal and disease states. |
|
|
Chemical, biochemical, pharmacological,toxicological,
clinical and therapeutic aspects of iron and other
metals, chelating agents and drugs and their
complexes. |
|
|
Conditions associated with metal imbalance,
transfusions and chelating drugs. |
|
|
Monitoring of chelation therapy with invasive and
non-invasive methods (e.g. MRI, Squid-
Biosusceptometry,"Free" iron etc) |
|
|
Heavy metals and radioactive metalsñToxicity and
metabolic aspects. |
|
|
Diagnosis and prevention of the toxicity of
chelating drugs and metal inbalance |
|
|
Metal ions in health, disease and diagnostic
medicine |
|
|
Biology, pharmacology and toxicology of metals and
chelators |
|
|
Free radicals in biology and medicine: the role of
antioxidants |
|
|
Recent advances in thalassaemia (all aspects) |
|
|
Cancer chemotherapy and chelation |
|
|
Epidemiological aspects of chelation therapy in
thalassaemia and other diseases |
|
|
Psychological aspects of chelation and other drug
therapy in thalassaemia and other diseases |
|
|
Thalassaemia patient and parents meetingñExpert
panel question/answer session |
